Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

NEW YORK, December 30, 2025, 1:14 PM ET — Regular session

Vipshop Holdings Limited (VIPS) shares fell about 5% on Tuesday, trading around $18.39 in afternoon dealings.

The drop came in a muted U.S. session with year-end liquidity thin, leaving single-stock swings more pronounced than usual. Reuters

Investors are also waiting for the Federal Reserve’s minutes from its Dec. 9-10 meeting due later Tuesday, looking for signals on how policymakers see the 2026 path for interest rates. Reuters

Jefferies analyst Thomas Chong reiterated a buy rating and a $22.60 price target on Vipshop. Jefferies expects fourth-quarter revenue at the low end of management’s guidance, citing a tougher year-ago comparison and the timing of Chinese New Year promotions, and said Super VIP (SVIP), its paid loyalty membership tier, should keep growing at a double-digit pace.

U.S.-listed China peers were mixed: Alibaba was down about 0.4%, JD.com fell about 1.5%, and PDD Holdings was little changed. The KraneShares CSI China Internet ETF was flat, while the iShares China Large-Cap ETF edged up.

Vipshop last reported results on Nov. 20, saying third-quarter revenue rose 3.4% to RMB21.4 billion and net income attributable to shareholders climbed 16.8% to RMB1.2 billion. “We successfully regained business growth in the third quarter,” Chief Executive Officer Eric Shen said.

For the fourth quarter, Vipshop forecast net revenues of RMB33.2 billion to RMB34.9 billion, a range that implies roughly flat to 5% growth from a year earlier.

Guidance is a company’s own forecast, and coming in at the low end can still rattle investors if the market had started to price in a stronger finish to the year.

Traders will watch whether the stock steadies after Tuesday’s dip, or whether selling builds into the close as year-end positioning continues.

In currency markets, the dollar firmed ahead of the Fed minutes as traders weighed the outlook for U.S. rates and the yuan’s recent weakness. Reuters

Beyond the minutes, investors are focused on signals that move China consumer demand — from the promotional calendar around Lunar New Year to any policy headlines that affect spending.

Stock Market Today

  • CorMedix (CRMD) Shares Fall 43% Yet Show Signs of Deep Undervaluation
    January 20, 2026, 6:53 AM EST. CorMedix (CRMD) has seen its share price drop by 43.6% in 30 days and nearly 45.7% over the past year despite a positive three-year return of 56.2%. The decline comes amid volatility tied to market sentiment and its pharmaceutical product pipeline prospects. A Discounted Cash Flow (DCF) analysis by Simply Wall St estimates an intrinsic value of $72.83 per share, implying the stock is roughly 90.7% undervalued compared to the recent price near $6.78. The DCF model forecasts CorMedix's free cash flow rising to $241.8 million by 2030. Investors should weigh CorMedix's current valuation against industry peers and growth risks. The stock's ongoing P/E ratio and pipeline developments remain key watch points for value assessment.
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today
Previous Story

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

France vows stable electricity bills in 2026 — but new charges could still push costs up
Next Story

France vows stable electricity bills in 2026 — but new charges could still push costs up

Go toTop